GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaLundensis AB (XSAT:PHAL BTA) » Definitions » Tariff Resilience Score

PharmaLundensis AB (XSAT:PHAL BTA) Tariff Resilience Score : 0/10 (As of Jun. 28, 2025)


View and export this data going back to . Start your Free Trial

What is PharmaLundensis AB Tariff Resilience Score?

PharmaLundensis AB has the Tariff Resilience Score of 0, which implies that the company might have .

PharmaLundensis AB has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes PharmaLundensis AB might have .


PharmaLundensis AB  (XSAT:PHAL BTA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

PharmaLundensis AB Tariff Resilience Score Related Terms

Thank you for viewing the detailed overview of PharmaLundensis AB's Tariff Resilience Score provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaLundensis AB Business Description

Traded in Other Exchanges
Address
PharmaLundensis AB, Scheelevagen 2, Lund, SWE, 223 63
PharmaLundensis AB is a Sweden based drug manufacturing company, The company focuses on the development and marketing of pharmaceuticals. It is engaged in developing drugs for the lung diseases, such as chronic obstructive pulmonary disease and asthma, as well as drugs for mercury toxicology.

PharmaLundensis AB Headlines

No Headlines